/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS./
VICTORIA, July 18, 2017 /CNW/ - Emerald Health Therapeutics, Inc. (TSXV: EMH, OTCQX: EMHTF) ("Emerald" or the "Company") announces that it has filed an amended and restated final base shelf prospectus (the "Amended Prospectus") with the securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland and Labrador, amending and restating the base shelf prospectus filed by the Company on January 25, 2017 (the "Original Prospectus") with such securities regulatory authorities.
As announced on February 10, 2017, April 20, 2017 and April 21, 2017, the Company has issued an aggregate of $40,940,673 of Securities (as defined below) under the Original Prospectus and therefore, prior to the filing of the Amended Prospectus, had an aggregate of $9,059,327 of Securities unallocated under the Original Prospectus. The Amended Prospectus will allow the Company, in the aggregate, to offer, from time to time, up to $150,000,000 of Securities of which $109,059,327 is unallocated as of the date hereof during the period ending February 25, 2019 that the Amended Prospectus remains effective (the "Effective Period").
The Amended Prospectus will enable the Company to make offerings of up to $150,000,000 of common shares, preferred shares, debt securities, warrants, units or subscription receipts of the Company (collectively, the "Securities") or a combination thereof from time to time, separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of the offering and as set out in an accompanying prospectus supplement during the Effective Period. The specific terms of any future offering will be established in a prospectus supplement to the Amended Prospectus, which supplement will be filed with the applicable Canadian securities regulatory authorities. The net proceeds from any sale of any securities will be used for purposes as set out in the applicable Amended Prospectus supplement.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.
A copy of the Amended Prospectus can be found under the Company's profile on sedar.com or may be obtained from the Company upon written request from the contact below.
Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) operates primarily through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary of the Company and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Botanicals is authorized to produce and sell both dried medical cannabis flowers and medical cannabis oils in Canada. Botanicals currently operates an indoor facility in Victoria, British Columbia, with plans for expansion on a 32-acre property in Metro Vancouver and a joint venture with Village Farms utilizing 25 acres of greenhouse complex in Delta, BC. Botanicals is one of Canada's most medically focused licensed producers, with a team of highly qualified management experienced in pharmaceutical drug discovery, development and distribution. Emerald's vision is to be a leading provider of cannabis products through its production capabilities, proprietary genetics and intellectual property, value added products and branding, and superb customer experience.
Please visit https://www.emeraldhealth.ca/ for more information.
Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".
We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements regarding the filing and effectiveness of any potential prospectus supplement; the amount and terms of any securities to be offered; the Company's plans for expansion; and the Company's vision to be a leading provider of cannabis.
The Company does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, the potential offering of any securities by the Company; uncertainty with respect to the completion of any future offering; the ability to obtain applicable regulatory approval for any contemplated offerings; the ability of the Company to negotiate and complete future funding transactions; variations in market conditions; failure of the federal government to approve legislation legalizing sales of non-therapeutic adult-use cannabis; failure to obtain Health Canada and other regulatory approvals; failure to obtain necessary financing; results of production and sale activities; the Company's historical experience with medical marijuana operations; results of scientific research; uninsured risks; regulatory changes; difficulties in construction or in obtaining qualified contractors to complete construction or conversion of facilities; availability of production facilities; timeliness of government approvals and the granting of permits and licenses; changes in prices and costs; actual operating and financial performance of facilities; equipment and processes relative to specifications and expectations; as well as the other risk factors set out in the Amended Prospectus and the Company's annual information form and other filing with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.
"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."
SOURCE Emerald Health Therapeutics, Inc.
For further information: Sandy Pratt, CFO, 250-818-9838, [email protected]